News

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...
Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...
Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.
Siemens Healthineers has deployed its first mobile stroke unit in the U.S., with an ambulance equipped with its own CT ...
Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...
In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...
The FDA and Stealth look set to relitigate the debate, with the biotech planning to file for approval once again. Stealth has ...
Instead, Stealth submitted a new drug application seeking approval of elamipretide, and the FDA issued its refusal-to-file ...
A Dutch neuromodulation developer has raised $60 million to complete the development of its minimally invasive implant for ...
After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...